EC Pharmacology and Toxicology

Review Article Volume 11 Issue 1 - 2023

Anticholinergic Syndrome: An Under Diagnosed Harmful Condition in the Perioperative and ICU Settings

Duraiyah Thangathurai1*, Maggy Riad2, Peter Roffey3, Shehan Thangaratnam4, Eugenia Ayrian5, Ashraf Sedra6, Earl Strum7 and Vladimir Zelman8

1Professor of Clinical Anesthesiology, Surgery and Urology, Director of Department Development, Department of Anesthesiology, University of Southern California, LA, CA, USA
2Professor Clinical Anesthesiology, UCLA Medical Center, LA, CA, USA
3Associate Professor of Clinical Anesthesiology, Department of Anesthesiology, University of Southern California, LA, CA, USA
4San Bernardine’s Medical Center, LA, CA, USA
5Associate Professor of Clinical Anesthesiology, Director of KSOM Anesthesia Medical Student Rotation, Department of Anesthesiology, University of Southern California, LA, CA, USA
6Clinical Associate Professor of Anesthesiology (Clinical Educator), Chief of Anesthesiology for Transplantation and OR Clinical Coordinator, Residency Site Director - Keck, Department of Anesthesiology, University of Southern California, LA, CA, USA
7Clinical Professor of Anesthesiology and Population and Public Health Science (Clinician Educator), Director, Employee Health, Department of Anesthesiology, University of Southern California, LA, CA, USA
8Clinical Professor of Anesthesiology, Department of Anesthesiology, University of Southern California, LA, CA, USA

*Corresponding Author: Duraiyah Thangathurai, Professor of Clinical Anesthesiology, Surgery and Urology, Director of Department Development, Department of Anesthesiology, University of Southern California, LA, CA, USA.
Received: November 30, 2022; Published: December 16, 2022



Medication-induced anticholinergic syndrome may result from the concurrent administration of a single or several drugs with anticholinergic properties. It is associated with central and peripheral signs and symptoms. Central anticholinergic syndrome involves the brain structures whereas peripheral anticholinergic syndrome affects peripheral vital organ systems. Anticholinergic syndrome is commonly occurred in perioperative settings and ICU settings because there is greater need for multiple medications (polypharmacy).

Commonly used medications which have direct anticholinergic effects are atropine, scopolamine (hyoscine), and glycopyrrolate. Other medications with anticholinergic side effects are antipsychotics, antidepressants, antihistamines, anesthetic agents, sedatives, analgesics, antiemetics, anti-parkinsonian drugs, anticonvulsants, anti-dysrhythmics, medications used for urinary dysfunction, GI tract, bronchodilators, eye medications etc. The incidence in the elderly population is higher because of the decrease in cholinergic reserve and activity with the aging process. Polypharmacy incidence is highest in the ICU and post-operative settings, especially on mechanically ventilated patients. This condition is historically under-diagnosed by physicians, nurses, and other medical personnel despite the increasing use of these drugs in an aging population [1]. The incidence in the elderly population is higher because of the decrease in cholinergic reserve and decreased cholinergic receptors. Current reports indicate more than 600 medications have anti-cholinergic side effects [2].

Keywords: Anticholinergics; ICU Settings; Polypharmacy; Delirium; Anticholinergic Burden; Elderly Patients

  1. Holden RJ., et al. “Understanding older adults' medication decision making and behavior: a study on over-the-counter (OTC) anticholinergic medications”. Research in Social and Administrative Pharmacy1 (2019): 53-60.
  2. Migirov A and Datta AR. “Physiology, anticholinergic reaction”. Stat Pearls (2021).
  3. Cook B and Spence AA. “Post-operative central anticholinergic syndrome”. European Journal of Anaesthesiology1 (1997): 1-2.
  4. Schneck HJ and Rupreht J. “Central anticholinergic syndrome (CAS) in anesthesia and intensive care”. Acta Anaesthesiologica Belgica3 (1989): 219-228.
  5. De Keulenaer BL., et al. “Central anticholinergic syndrome in the intensive care unit”. European Journal of Anaesthesiology6 (2004): 499-501.
  6. Lopez-Alvarez J., et al. “Anticholinergic Drugs in Geriatric Psychopharmacology”. Frontiers in Neuroscience (2019): 13.
  7. Vondeling AM., et al. “Anticholinergic drug exposure at intensive care unit admission affects the occurrence of delirium. A prospective cohort study”. European Journal of Internal Medicine 78 (2020): 121-126.
  8. Feinberg M. “The Problems of Anticholinergic Adverse Effects in Older Patients”. Drugs and Aging4 (1993): 335-348.
  9. Schliebs R and Arendt T. “The cholinergic system in aging and neuronal degeneration”. Behavioural Brain Research2 (2011): 555-563.
  10. Thangathurai D., et al. “Pain relief and sedation in the intensive care unit”. Seminars in Anesthesia, Perioperative Medicine and Pain1 (1999): 81-86.
  11. Carnahan RM., et al. “The anticholinergic drug scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity”. The Journal of Clinical Pharmacology12 (2006): 1481-1486.
  12. Bishara D., et al. “Anticholinergic effect on cognition (AEC) of drugs commonly used in older people”. International Journal of Geriatric Psychiatry6 (2017): 650-656.
  13. Liu AKL., et al. “Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease”. Acta Neuropathologica4 (2015): 527-540.
  14. Mesulam MM. “Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease”. Journal of Comparative Neurology18 (2013): 4124-4144.
  15. Yano JM., et al. “Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis”. Cell2 (2015): 264-276.
  16. Mayer EA. “Gut feelings: the emerging biology of gut–brain communication”. Nature Reviews Neuroscience8 (2011): 453-466.
  17. Korsapati H., et al. “Cholinergic stimulation induces asynchrony between the circular and longitudinal muscle contraction during esophageal peristalsis”. American Journal of Physiology-Gastrointestinal and Liver Physiology3 (2008): G694-G698.
  18. Parkman H., et al. “Cholinergic effects on human gastric motility”. Gut3 (1999): 346-354.
  19. Kummer W., et al. “The epithelial cholinergic system of the airways”. Histochemistry and Cell Biology2 (2008): 219-234.
  20. Kudlak M and Tadi P. “Physiology, muscarinic receptor”. Stat Pearls Publishing (2021).
  21. Haga T. “Molecular properties of muscarinic acetylcholine receptors”. The Journal was split to the Proceedings of the Japan Academy, Series A and Series B6 (2013): 226-256.
  22. Moulton BC and Fryer AD. “Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD”. British Journal of Pharmacology (2020): 23.
  23. Buels KS and Fryer AD. “Muscarinic receptor antagonists: effects on pulmonary function”. Muscarinic Receptors (2012): 317-341.
  24. Bowie MW and Slattum PW. “Pharmacodynamics in older adults: A Review”. The American Journal of Geriatric Pharmacotherapy3 (2007): 263-303.
  25. Karimi S., et al. “Anticholinergic burden: clinical implications for seniors and strategies for clinicians”. The Consultant Pharmacist8 (2012): 564-582.
  26. Eglen RM. “Muscarinic receptors and gastrointestinal tract smooth muscle function”. Life Sciences22-23 (2001): 2573-2578.
  27. Cebron Lipovec N., et al. “Anticholinergic burden in children, adults and older adults in Slovenia: A Nationwide database study”. Scientific Reports1 (2020): 1-8.
  28. Garpestad E and Devlin JW. “Polypharmacy and delirium in critically ill older adults”. Clinics in Geriatric Medicine2 (2017): 189-203.
  29. Rudolph JL., et al. “The anticholinergic risk scale and anticholinergic adverse effects in older persons”. Archives of Internal Medicine5 (2008): 508-513.
  30. Boustani M., et al. “Impact of anticholinergics on the aging brain: a review and practical application”. Aging Health3 (2008): 311-320.
  31. Lee JH., et al. “Anticholinergic cognitive burden as a predictive factor for in-hospital mortality in older patients in Korea”. Annals of Geriatric Medicine and Research1 (2020): 20.
  32. Hilmer SN., et al. “A drug burden index to define the functional burden of medications in older people”. Archives of Internal Medicine8 (2007): 781-787.
  33. Pandharipande PP., et al. “Long-term cognitive impairment after critical illness”. New England Journal of Medicine14 (2013): 1306-1316.
  34. Gordon SM., et al. “Clinical identification of cognitive impairment in ICU survivors: Insights for intensivists”. Intensive Care Medicine11 (2004): 1997-2008.
  35. Risacher SL., et al. “Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults”. JAMA Neurology6 (2016): 721.
  36. Pfistermeister B., et al. “Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients”. PLOS ONE2 (2017): e0171353.
  37. Broder JC., et al. “Anticholinergic medication burden and cognitive function in participants of the ASPREE study”. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy2 (2022): 134-144.
  38. Campbell N., et al. “The cognitive impact of anticholinergics: A clinical review”. Clinical Interventions in Aging (2009): 225-233.
  39. Kumpula EK., et al. “Anticholinergic Drug Use and Mortality Among Residents of Long-Term Care Facilities: A Prospective Cohort Study”. The Journal of Clinical Pharmacology2 (2011): 256-263.
  40. Kalisch Ellett LM., et al. “Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia”. Journal of the American Geriatrics Society10 (2014): 1916-1922.
  41. Gray SL., et al. “Cumulative use of strong anticholinergics and incident dementia”. JAMA Internal Medicine3 (2015): 401.
  42. Salahudeen MS., et al. “Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review”. BMC Geriatrics1 (2015): 31.
  43. Hayhurst CJ., et al. “Intensive care unit delirium: a review of diagnosis, prevention, and treatment”. Anesthesiology6 (2016): 1229-1241.
  44. Liang S., et al. “Effects of nonpharmacological delirium-prevention interventions on critically ill patients' clinical, psychological, and family outcomes: A systematic review and meta-analysis”. Australian Critical Care4 (2021): 378-387.
  45. Burry LD., et al. “Delirium and exposure to psychoactive medications in critically ill adults: A multi-centre observational study”. Journal of Critical Care 42 (2017): 268-274.
  46. Muller A., et al. “Long-term cognitive impairment after ICU treatment: a prospective longitudinal cohort study (Cog-I-CU)”. Scientific Reports1 (2020): 1-10.
  47. Breit S., et al. “Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorder”. Frontiers in Psychiatry (2018): 44.
  48. Carabotti M., et al. “The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems”. Annals of Gastroenterology 28 (2015): 203-209.

Duraiyah Thangathurai.,et al. Anticholinergic Syndrome: An Under Diagnosed Harmful Condition in the Perioperative and ICU Settings. EC Pharmacology and Toxicology 11.1 (2023): 06-14.